Frenaler

Quick links to important sections

Frenaler

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Frenaler

What is Frenaler? (Desloratadine Overview)

Property Description
Active ingredient Desloratadine
Form Tablet, Oral solution, Syrup
Pharmacological class Second-generation H₁-antihistamine
General Purpose Modulating allergic response
Origin Synthetic compound

What is Frenaler and Its Composition?

Frenaler is the trade name for a synthetic pharmaceutical preparation whose active ingredient is Desloratadine. This medicine is classified as a systemic medication, intended to be taken by the oral route, and is commonly available in basic dosage forms such as a tablet or an oral solution (syrup). The active compound, Desloratadine, is derived as the principal active metabolite of the older antihistamine, Loratadine. This confirms its status as a single-ingredient product, which utilizes the specific properties of the Desloratadine molecule to achieve its effects.


What Type of Antihistamine is Frenaler?

Frenaler belongs to the pharmacological class of second-generation H₁-antihistamines, establishing it as a modern anti-allergic agent. This classification signifies that it is a selective H₁-receptor antagonist, designed to efficiently block the action of the chemical histamine primarily in the periphery of the body. This means the medicine works by intercepting the chemical signal that triggers allergic symptoms.

Critically, its molecular structure renders it a non-sedating antihistamine because it minimizes unwanted penetration into the central nervous system, distinguishing it from older, first-generation agents. It is classified as a substance intended for the symptomatic treatment of allergic conditions. This drug is intended to reduce the discomfort experienced during an allergic episode.


What is the General Purpose of Desloratadine?

The general purpose of Desloratadine is to modulate the body's allergic response, providing systemic relief to restore comfort and function. Its primary function is the inhibition of histamine effects, reducing the severity and intensity of discomfort caused by the body's release of this inflammatory chemical. Clinical experience has established its reliability for daily allergy management, such as during typical seasonal allergen exposure. In addition to its core H₁-receptor blockade, secondary anti-inflammatory properties are noted. This combined action allows the medicine to effectively intercept the cascade of allergic signals, providing comprehensive relief by stabilizing the body's overreaction.

Regulatory References

  1. Desloratadine: MedlinePlus Drug Information

What side effects are possible with Frenaler?

Possible Side Effects and Safety Information

The safety profile of Frenaler (Desloratadine) is organized according to explicit frequency classifications defined in official regulatory documents. In clinical trials, the adverse event profile showed effects that were generally reported in only a small percentage of patients in excess of those treated with placebo.


Frequency-Classified Adverse Reactions

The most Common (ge1/100 to <1/10) adverse reactions documented in official labeling include headache, fatigue, and dry mouth [NIH DailyMed - DESLORATADINE tablet].

Reactions classified as Very Rare (<1/10,000) or Frequency Not Known (reported during post-marketing surveillance) are linked to several System-Organ Classes. These include Nervous System Disorders (e.g., dizziness, seizures, insomnia) and Gastrointestinal Disorders (e.g., nausea, vomiting, abdominal pain) [EMA - Summary of Product Characteristics].


Serious Adverse Reactions and Systemic Concerns

Rare but serious adverse reactions documented in regulatory sources include severe Hypersensitivity Reactions (such as anaphylaxis and angioedema) and effects on the Hepatobiliary System (such as hepatitis and elevated liver enzymes). Post-marketing reports also note occurrences involving the Cardiac System, including tachycardia (increased heart rate) and QT prolongation [EMA - Summary of Product Characteristics], [NIH DailyMed - DESLORATADINE tablet].


Population-Specific Safety Notes

Official labeling includes specific cautions for certain populations. Caution is required in patients with severe renal or hepatic impairment due to the potential for increased systemic exposure. The label also notes specific safety information for the pediatric population regarding a reported increased incidence of new-onset seizure [FDA - CLARINEX (desloratadine) Tablets]. Furthermore, the orally disintegrating tablet form may contain phenylalanine, which is relevant for individuals with Phenylketonuria (PKU) [NIH MedlinePlus Drug Information].

Overdose and Emergency Response

Frenaler Overdose and when to seek help

In cases of ingesting an amount of Frenaler (Desloratadine) exceeding the recommended dose, the officially documented manifestations are primarily an increased magnitude of effects seen at therapeutic levels. The most commonly reported sign of overdose is drowsiness (somnolence). However, regulatory safety documents note that overdose may be associated with severe outcomes affecting the cardiovascular and neurological systems. These include post-market reported effects such as tachycardia (rapid heart rate), palpitations, changes in cardiac electrical activity known as QT prolongation, and seizures. A specific concern cited in regulatory labeling is the increased incidence of new-onset seizure reported in the pediatric population, specifically in patients 0 to 19 years of age.


Emergency Action Required

Government health authorities provide clear instructions for situations involving severe overdose. Immediate medical attention is required if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. In such severe circumstances, you must immediately call emergency services (e.g., 911). For general questions or suspected overdose without these life-threatening signs, it is mandated to call the poison control helpline.


Official Management Considerations

Management procedures described in regulatory labeling specify that symptomatic and supportive treatment is recommended. Standard measures to remove the unabsorbed substance should be considered, as no specific antidote is known for Desloratadine overdose. Furthermore, regulatory documents specify a procedural limitation: the substance is not eliminated by haemodialysis.

Therapeutic Uses of Frenaler

What Frenaler Treats: Main Uses and Benefits

Frenaler (Desloratadine) is a therapeutic agent commonly used in settings marked by temporary physiological imbalance, applied in contexts where supportive relief for allergic symptom management is needed. It is considered relevant because it contributes to easing the overall symptom load and helps patients cope more steadily with disruptive episodes. The use of this medication is consistent with its official indications.

Frenaler is applied across domains where additional symptomatic support is needed, primarily focusing on allergic rhinitis (including seasonal and perennial forms) and chronic urticaria (hives). The medication is used for managing the symptom clusters that include sneezing, runny nose, nasal itching, and itchy, watery eyes associated with rhinitis, as well as the intense itching (pruritus) and may assist with the reduction of skin welts linked to chronic hives. The medication may assist with symptomatic control in situations where maintaining functional stability is key for routine activities.


Quick Fact: Relief for Itching (Pruritus) in Chronic Hives


Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Frenaler? (Official Regulatory Information)

Frenaler (desloratadine) eligibility is strictly defined by regulatory documents, setting clear guidelines for use across different populations and health conditions.

Contraindicated Populations

Use is contraindicated (must not be used) in individuals with known hypersensitivity to the active substance desloratadine, its precursor loratadine, or any inactive ingredients in the formulation. Certain oral formulations are also contraindicated in patients with hereditary problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Age-Related Eligibility

  • Adults and Adolescents (ge 12 years): Eligible for standard use.
  • Pediatric Use: Oral solution formulations may be approved for use in children as young as 6 months for specific conditions. However, the safety and efficacy of the film-coated tablets are not established in children below 12 years of age.

Condition-Specific Restrictions

  • Renal or Hepatic Impairment: Use requires caution in adult patients with severe renal insufficiency or hepatic impairment. Official regulatory guidelines recommend a dose adjustment (often every-other-day dosing) in these populations due to altered drug clearance.
  • Pregnancy and Lactation: Use during pregnancy is generally preferable to avoid as a precautionary measure. Desloratadine is known to pass into breast milk; therefore, a decision must be made to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Frenaler (Desloratadine) is defined by documented pharmacokinetic patterns and a specific pharmacodynamic caution. No drug-drug combinations are formally documented as contraindicated based solely on interaction risk for the single-ingredient product.

Metabolic and Transporter Interactions

Co-administration with certain substances can alter the exposure of Desloratadine. Medicines that inhibit the cytochrome P-450 enzyme system or the P-glycoprotein efflux transporter, such as ketoconazole, erythromycin, cimetidine, azithromycin, and fluoxetine, cause an increase in the plasma concentration of Desloratadine and its active metabolite. Regulatory documents state that despite this increase in exposure, no clinically relevant changes in the safety profile were observed during clinical trials.

Pharmacodynamic Effects and Restrictions

While clinical trials did not show Desloratadine potentiating the performance-impairing effects of alcohol, regulatory authorities recommend caution if alcohol is taken concomitantly. This restriction is based on post-marketing reports of alcohol intolerance. Furthermore, the label establishes that no mandatory timing separation is required for administration; the medicine may be taken with or without food, indicating the absence of a restrictive food interaction pattern.

Mechanism of Action

Peripheral H1 Receptor Blockade

This domain covers the primary molecular target: the Histamine H1 receptors ( H1-R) located predominantly in peripheral tissues. Frenaler's active molecule, Desloratadine, is a selective antagonist and inverse agonist that binds to and inactivates these receptors, interrupting the signal transmission initiated by the body's natural release of histamine. This core mechanism directly modulates the pathways that mediate capillary permeability and sensory nerve activation.

Secondary Anti-Inflammatory Modulation

This domain addresses the drug's mechanism beyond simple receptor blockade, focusing on its ability to modulate the cascade of sustained inflammation. Desloratadine modulates key steps in the inflammatory cascade by suppressing the generation and release of several pro-inflammatory cytokines (e.g., IL-4, IL-6, IL-8) and adhesion molecules (e.g., ICAM-1). This engagement with secondary mediators contributes to the modulation of processes that escalate the inflammatory response.

Mechanism of Central Selectivity

This domain explains the structural and distribution mechanism that dictates where the drug acts. The molecule's chemical properties and interaction with biological efflux systems (such as P-glycoprotein) limit its penetration of the blood-brain barrier (BBB). This mechanism ensures that the drug primarily engages peripheral H1-R, resulting in minimal interaction with central H1 functions.

Dosage and Administration Information

How to Use Frenaler

Frenaler (Desloratadine) is administered solely by the oral route. The medicine is available in various forms, including 5 mg film-coated tablets, orally disintegrating tablets (ODT), and an oral solution typically concentrated at 0.5 mg/mL. Adherence to the established dosing schedule, which is based on age and clinical condition, is essential for its correct use.


Official Administration Guidelines

Instruction Administration Details
Route of administration Oral (by mouth) only.
Standard Dosing Schedule Adults and Adolescents (12 years and older) use 5 mg once daily. Children 6–11 years use 2.5 mg once daily.
Timing in relation to meals May be taken with or without food.
Use Pattern Intermittent use is permitted for seasonal allergic rhinitis, where dosing is tied to the presence of symptoms. Continuous use is permitted for persistent conditions.

Procedural and Population-Specific Rules

Administration follows a once-daily (qDay) frequency pattern. The oral solution must be accurately measured using a calibrated dosing device, such as a dropper or syringe, to ensure the correct dose is delivered. Conversely, film-coated tablets should be swallowed whole.

Specific dose modification is documented for compromised renal or hepatic function in adults. In these instances, a starting dose of 5 mg every other day may be indicated. If a dose is missed, it should be taken when remembered, but a double dose must not be taken to compensate for the omission. The structural administration guidelines define a standardized, flexible intake protocol that supports both short-term and persistent usage patterns.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Frenaler

Evidence for Use in Allergic Rhinitis

The evidence base for Frenaler, which was studied for allergic rhinitis (including seasonal and perennial types), is primarily built on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time compared to a placebo.

Researchers focused on patient-reported outcomes describing perceived discomfort, such as total symptom scores for nasal symptoms (like sneezing and itching) and non-nasal symptoms (like itchy or watery eyes). Studies also monitored objective nasal airflow and broader outcomes reflecting daily functioning, such as quality of life (QoL) assessments. Findings describe patterns observed in the studies related to these reported symptom scores. While studies explored short-term changes, long-term outcomes are not fully established by the primary controlled trials, as follow-up durations were often limited to a few weeks.


Evidence for Use in Chronic Urticaria (Hives)

The research for Frenaler, which was studied for chronic urticaria (hives), is also primarily based on randomized, double-blind, placebo-controlled trials. This research was applied in studies examining patient-reported experiences in conditions characterized by fluctuating manifestations.

Primary outcomes included outcomes related to physical discomfort, with studies examining the severity of itching (pruritus) and tracking the number and size of skin lesions (welts). The studies also monitored outcomes reflecting daily functioning by assessing metrics such as sleep disturbance. Findings describe patterns observed in the studies related to the reported severity of itching and the appearance of welts in the observed populations.


Evidence in Special Populations and Research Gaps

Research examined the use of Frenaler in adolescents (age 12 and older) and separate controlled studies evaluated the pediatric population, including children as young as 6 months up to 11 years of age. Findings describe group patterns, not personal outcomes, in these populations. Data for infants under six months of age are insufficient, where the product's use has not been established through trials.

The main limitation of the current research is that there is limited information for long-term outcomes that may arise from continuous use over many months or years. Comparative evidence is also lacking in some contexts, meaning more research is needed to fully contextualize this treatment compared to all other options.

Frequently Asked Questions (FAQ)

Common questions about Frenaler (FAQ)

Q: How quickly should I expect Frenaler to start working?

Studies indicate that the antihistaminic effect of Frenaler's active ingredient, desloratadine, typically begins within one hour after administration. The concentration in the blood usually reaches its highest level about three hours after taking the medicine.

Q: How long does the effect of one dose of Frenaler typically last?

Frenaler is formulated to provide symptom relief that can last for up to 24 hours, which supports its once-daily use. Official pharmacokinetic information notes that it takes approximately 27 hours for half of the drug to be eliminated from the body.

Q: Can Frenaler interact with common over-the-counter pain relievers?

Regulatory documents list specific drug interactions with medicines that affect the metabolism of Frenaler (such as certain antibiotics or antifungals). There is no specific interaction documented in official labeling for common over-the-counter pain relievers like ibuprofen or acetaminophen.

Q: Are there any specific vitamins or supplements that Frenaler interacts with?

Official interaction profiles mainly focus on prescription medicines that can alter how the body processes Frenaler. No specific interaction with general vitamins, minerals, or dietary supplements is documented in core regulatory labeling.

Q: Does alcohol interact with Frenaler?

While clinical trials did not show that Frenaler increases the performance-impairing effects of alcohol, official regulatory documents recommend caution if alcohol is taken concomitantly. This caution is based on post-marketing reports that indicate alcohol intolerance may occur in some individuals.

Q: What are the signs of a severe allergic reaction to Frenaler?

Rare but serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported in official documents. Signs reported in connection with these severe reactions include swelling of the face, tongue, or throat, difficulty breathing, or a widespread rash.

Q: What is the difference between a common side effect and a serious one for Frenaler?

Common side effects are those reported in a measurable percentage of patients in clinical trials, like headache or dry mouth. Serious adverse reactions, documented in official safety information, involve major body systems (such as the liver or heart) and are typically reported very rarely during post-marketing surveillance.

Q: How long after stopping Frenaler does it take for the drug to leave my system?

The time it takes for a substance to leave the system is related to its half-life, which for Frenaler's active ingredient is about 27 hours. As it takes several half-lives for a substance to be substantially cleared, the medicine remains in the system for some time after the last dose.

Q: Does Frenaler interact with common birth control pills?

Regulatory documents do not indicate a specific interaction between Frenaler and hormonal birth control pills (oral contraceptives). Regulatory documents do not indicate that Frenaler alters the effectiveness of hormonal birth control pills.

Q: Can Frenaler cause changes in blood pressure?

The single-ingredient Frenaler formulation is not specifically linked to changes in blood pressure. However, very rare post-marketing reports have included occurrences of tachycardia (increased heart rate) and palpitations, which relate to the cardiovascular system.

Q: Does Frenaler treat the cause of the problem or just the symptoms?

Frenaler is described in official documentation as providing symptomatic relief for allergic conditions. Its mechanism of action works by modulating the body's allergic response, intercepting the chemical signals (like histamine) that directly cause allergic symptoms.

Q: Is Frenaler generally considered safe for older adults (seniors)?

Official labeling for geriatric use notes that while older patients may have slightly higher concentrations of the drug in their blood, this difference was not considered clinically important. While no dose adjustment is generally required for age alone, regulatory guidelines note that caution is advised for patients with severe kidney or liver impairment.

Q: Have there been any major studies on the long-term use of Frenaler?

The primary clinical trials used to establish the effectiveness of Frenaler were short-term, typically lasting only a few weeks. Regulatory summaries indicate that there is limited information available regarding long-term outcomes that may arise from continuous use over many months or years.

Q: Can Frenaler make me feel dizzy or affect my balance?

Dizziness has been reported as an adverse effect in clinical trial and post-marketing data. While official documents list dizziness, they do not specifically mention effects on a person's balance.

Q: Are there any foods I should avoid while taking Frenaler?

Clinical studies have shown that Frenaler's absorption is not affected by food, meaning it can be taken with or without a meal. A specific study also found that grapefruit juice does not substantially affect the bioavailability of the active ingredient.

Q: Why do some people say Frenaler causes an upset stomach?

Adverse events related to the stomach and digestive system have been reported in official documents, classified as gastrointestinal disorders. These include reported instances of abdominal pain, nausea, and vomiting. Official sources document the reported effects but do not explain the specific reason for their occurrence.

Q: Does Frenaler have a 'black box warning' in the US?

Based on the official FDA labeling, the single-ingredient formulation of Frenaler's active ingredient, Desloratadine, does not carry a 'Boxed Warning' (often called a 'black box warning').

Q: Is Frenaler available as a generic medicine?

Yes, the active ingredient in Frenaler, Desloratadine, has been approved for generic versions in the US and is available from various manufacturers in addition to the brand-name product.

Q: Are there any official restrictions on driving or operating machinery while on Frenaler?

Official labeling states that no impairment of driving ability was observed in clinical trials. However, official labeling informs patients that because a very rare incidence of drowsiness is reported, this could potentially affect the ability to drive or use machinery.

Q: If I have other health problems (comorbidities), is Frenaler still appropriate?

Official regulatory documents list specific cautions for individuals with certain health conditions, notably those with severe renal or hepatic impairment (kidney or liver issues) and a specific caution related to new-onset seizures. The appropriateness of Frenaler for other, general health conditions beyond those listed is not specifically detailed in official labeling.

Q: Is Frenaler known to affect sleep patterns or cause insomnia?

Although the drug is classified as non-sedating, insomnia (difficulty falling or staying asleep) has been reported in post-marketing surveillance or in clinical trials. This is generally classified as a very rare or frequency not known effect.

Q: Is there a maximum amount of time someone can safely use Frenaler?

Frenaler is approved for both intermittent use (as needed) and continuous use for persistent conditions. While continuous use is permitted, regulatory summaries note that information on the long-term outcomes from use over many years is limited in the primary controlled trials.

Q: Does Frenaler have any known interactions with herbal supplements like St. John's Wort?

Official labeling does not list a specific interaction with St. John's Wort or other herbal products. The documented interactions are primarily with certain pharmaceutical agents that affect the way the body processes the medicine.

Q: Is it safe to take Frenaler if I have glaucoma or heart disease?

Frenaler is not formally contraindicated for general heart disease or glaucoma. However, post-marketing reports include very rare occurrences of certain cardiac effects like tachycardia (increased heart rate) and QT prolongation, which are systemic concerns noted in the official safety information.

Q: Why is Frenaler sometimes given the brand name [Frenaler Brand Name]?

Frenaler is a brand name used for marketing and identification of the product containing the active substance, Desloratadine. Other brand names may be used in different regions based on local regulatory approval for the same active ingredient.

How should Frenaler be stored and disposed of?

Storage and Disposal of Frenaler (Desloratadine)

The storage and disposal procedures for Frenaler are defined by regulatory labeling to maintain product stability and ensure public safety.


Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect the medicine from excessive moisture and light; strictly do not freeze.
Container Keep the product in its original, tightly closed container.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be managed according to official guidance. The preferred method is using a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, sealed, and discarded in the household trash. Do not flush Frenaler down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Frenaler found in:

A-Z Index: